U.S. Regulators Beef Up Investigation of Corporate Bribery & Corruption Overseas
This article was originally published in PharmAsia News
Executive Summary
Pharmaceutical companies have been battered by government and congressional investigations of their domestic marketing practices. They now face increased scrutiny on another front as the Department of Justice and the Securities and Exchange Commission are stepping up investigations of corporate corruption and bribery abroad